JP2006504736A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006504736A5 JP2006504736A5 JP2004543231A JP2004543231A JP2006504736A5 JP 2006504736 A5 JP2006504736 A5 JP 2006504736A5 JP 2004543231 A JP2004543231 A JP 2004543231A JP 2004543231 A JP2004543231 A JP 2004543231A JP 2006504736 A5 JP2006504736 A5 JP 2006504736A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- hydrogen
- alkyl
- haloalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 56
- 229910052801 chlorine Inorganic materials 0.000 claims description 33
- 229910052731 fluorine Inorganic materials 0.000 claims description 33
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 32
- 229910052794 bromium Inorganic materials 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000001188 haloalkyl group Chemical group 0.000 claims description 7
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 7
- 229940002612 prodrug Drugs 0.000 claims description 7
- 239000000651 prodrug Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 5
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 5
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims 37
- 238000000034 method Methods 0.000 claims 15
- 102000003998 progesterone receptors Human genes 0.000 claims 12
- 108090000468 progesterone receptors Proteins 0.000 claims 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 7
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- SOZVIENSJBLZHW-UHFFFAOYSA-N 5-(1,3-dithian-2-ylidene)-7,9-difluoro-2,2,4-trimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC(F)=C2OC1=C1SCCCS1 SOZVIENSJBLZHW-UHFFFAOYSA-N 0.000 claims 1
- STJIWXRRNMRBHR-UHFFFAOYSA-N 5-(1,3-dithian-2-ylidene)-7-fluoro-2,2,4-trimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC=CC(F)=C2OC1=C1SCCCS1 STJIWXRRNMRBHR-UHFFFAOYSA-N 0.000 claims 1
- RITVYBKZHUTSEL-UHFFFAOYSA-N 5-(1,3-dithian-2-ylidene)-7-fluoro-2,2-dimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C12=C3C=CC(C)(C)NC3=CC=C2C2=CC=CC(F)=C2OC1=C1SCCCS1 RITVYBKZHUTSEL-UHFFFAOYSA-N 0.000 claims 1
- UBNPHBBSESDOSW-UHFFFAOYSA-N 5-(1,3-dithian-2-ylidene)-8-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C=1C(OC)=CC=C(C2=C3C=4C(C)=CC(C)(C)NC=4C=C2)C=1OC3=C1SCCCS1 UBNPHBBSESDOSW-UHFFFAOYSA-N 0.000 claims 1
- NTCBYBDADUSXSB-UHFFFAOYSA-N 5-(1,3-dithian-2-ylidene)-9-fluoro-2,2,4-trimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC=C2OC1=C1SCCCS1 NTCBYBDADUSXSB-UHFFFAOYSA-N 0.000 claims 1
- DJUZJVGDGCDWRB-UHFFFAOYSA-N 5-cyclohexylidene-7,9-difluoro-2,2,4-trimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC(F)=CC(F)=C2OC1=C1CCCCC1 DJUZJVGDGCDWRB-UHFFFAOYSA-N 0.000 claims 1
- FCWCIACWFSZKON-UHFFFAOYSA-N 5-cyclohexylidene-7-fluoro-2,2,4-trimethyl-1h-chromeno[3,4-f]quinoline Chemical compound C12=C3C(C)=CC(C)(C)NC3=CC=C2C2=CC=CC(F)=C2OC1=C1CCCCC1 FCWCIACWFSZKON-UHFFFAOYSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940126657 Compound 17 Drugs 0.000 claims 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000033830 Hot Flashes Diseases 0.000 claims 1
- 206010060800 Hot flush Diseases 0.000 claims 1
- 206010027514 Metrorrhagia Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims 1
- 229940125773 compound 10 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940126086 compound 21 Drugs 0.000 claims 1
- 229940125833 compound 23 Drugs 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000035558 fertility Effects 0.000 claims 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 12
- 0 CC(*(C)C(C)(*)*C(*1)=C2Oc3c(*)c(*)c(C)cc3C3C2=C(C(*)=CC2(*)N4*2)C4=C*3)C1(*=C)O* Chemical compound CC(*(C)C(C)(*)*C(*1)=C2Oc3c(*)c(*)c(C)cc3C3C2=C(C(*)=CC2(*)N4*2)C4=C*3)C1(*=C)O* 0.000 description 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41814002P | 2002-10-11 | 2002-10-11 | |
| PCT/US2003/024416 WO2004033459A1 (en) | 2002-10-11 | 2003-08-04 | 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO[3,4-f]QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006504736A JP2006504736A (ja) | 2006-02-09 |
| JP2006504736A5 true JP2006504736A5 (enExample) | 2006-09-21 |
Family
ID=32094152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004543231A Pending JP2006504736A (ja) | 2002-10-11 | 2003-08-04 | 選択的プロゲステロンレセプター調節化合物としての５−（１’，１’−シクロアルキル／アルケニル）メチリデン１，２−ジヒドロ−５Ｈ−クロメノ［３，４−ｆ］キノリン |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7084151B2 (enExample) |
| EP (1) | EP1558618A1 (enExample) |
| JP (1) | JP2006504736A (enExample) |
| AR (1) | AR040783A1 (enExample) |
| AU (1) | AU2003258047A1 (enExample) |
| CA (1) | CA2501833A1 (enExample) |
| MX (1) | MXPA05003800A (enExample) |
| WO (1) | WO2004033459A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| AU2003258050A1 (en) * | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds |
| EP1558618A1 (en) * | 2002-10-11 | 2005-08-03 | Ligand Pharmaceuticals, Inc. | 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
| MXPA06001751A (es) * | 2003-08-22 | 2006-05-12 | Ligand Pharm Inc | Derivados de 6-cicloamino-2-quinolinona como compuestos moduladores de receptor de androgeno. |
| AP2949A (en) | 2006-03-07 | 2014-07-31 | Shroff Geeta | Compositions comprising human embryonic stem cellsand their derivatives, methods of use, and method s of preparation |
| EA201070715A1 (ru) * | 2007-12-20 | 2011-02-28 | Тева Вимен'С Хелс, Инк. | Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808139A (en) | 1992-04-21 | 1998-09-15 | Ligand Pharmaceuticals Incorporated | Non-steroid progesterone receptor agonist and antagonist and compounds and methods |
| US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
| US5693646A (en) | 1994-12-22 | 1997-12-02 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
| ATE269336T1 (de) * | 1994-12-22 | 2004-07-15 | Ligand Pharm Inc | Steroidrezeptor-modulator verbindungen und methoden |
| JPH11209735A (ja) * | 1998-01-28 | 1999-08-03 | Dow Corning Toray Silicone Co Ltd | フイルム状シリコーンゴム接着剤及び接着方法 |
| DE69904804T2 (de) * | 1998-02-13 | 2003-11-06 | Abbott Laboratories, Abbott Park | Glucocorticoid selektive entzündungshemmende mittel |
| US6380207B2 (en) * | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| US6001846A (en) | 1998-02-17 | 1999-12-14 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
| US6093825A (en) | 1998-05-27 | 2000-07-25 | American Home Products | Methods for preparation of 1,2-dihydroquinolines |
| US6093826A (en) | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
| US6423699B1 (en) | 1999-05-04 | 2002-07-23 | American Home Products Corporation | Combination therapies using benzimidazolones |
| US6380178B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Cyclic regimens using cyclocarbamate and cyclic amide derivatives |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| WO2000066592A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6329416B1 (en) | 1999-05-04 | 2001-12-11 | American Home Products Corporation | Combination regimens using 3,3-substituted indoline derivatives |
| US6444668B1 (en) | 1999-05-04 | 2002-09-03 | Wyeth | Combination regimens using progesterone receptor modulators |
| US6399593B1 (en) | 1999-05-04 | 2002-06-04 | Wyeth | Cyclic regimens using cyclic urea and cyclic amide derivatives |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6319912B1 (en) | 1999-05-04 | 2001-11-20 | American Home Products Corporation | Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides |
| EP1173213A1 (en) | 1999-05-04 | 2002-01-23 | American Home Products Corporation | Compositions containing benzimidazolones and progestogens |
| SI1173210T1 (en) | 1999-05-04 | 2005-02-28 | Wyeth | Contraceptive compositions containing antiprogestinic and progestinic |
| US6369056B1 (en) | 1999-05-04 | 2002-04-09 | American Home Products Corporation | Cyclic urea and cyclic amide derivatives |
| US6306851B1 (en) | 1999-05-04 | 2001-10-23 | American Home Products Corporation | Cyclocarbamate and cyclic amide derivatives |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
| US6358947B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Tetracyclic progesterone receptor modulator compounds and methods |
| US6462032B1 (en) | 1999-05-04 | 2002-10-08 | Wyeth | Cyclic regimens utilizing indoline derivatives |
| US6339098B1 (en) | 1999-05-04 | 2002-01-15 | American Home Products Corporation | 2,1-benzisothiazoline 2,2-dioxides |
| US6380235B1 (en) | 1999-05-04 | 2002-04-30 | American Home Products Corporation | Benzimidazolones and analogues |
| US6417214B1 (en) | 1999-05-04 | 2002-07-09 | Wyeth | 3,3-substituted indoline derivatives |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US6172241B1 (en) | 1999-10-15 | 2001-01-09 | Ligand Pharmaceuticals Incorporated | Process for the preparation of 1,2-dihydroquinolines |
| UA73119C2 (en) | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| EP1558618A1 (en) | 2002-10-11 | 2005-08-03 | Ligand Pharmaceuticals, Inc. | 5-(1 ,1 -CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO- 5H /-CHROMENO[3,4-f ] QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS |
| AU2003258050A1 (en) | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds |
-
2003
- 2003-08-04 EP EP03808050A patent/EP1558618A1/en not_active Withdrawn
- 2003-08-04 MX MXPA05003800A patent/MXPA05003800A/es unknown
- 2003-08-04 WO PCT/US2003/024416 patent/WO2004033459A1/en not_active Ceased
- 2003-08-04 CA CA002501833A patent/CA2501833A1/en not_active Abandoned
- 2003-08-04 AR AR20030102796A patent/AR040783A1/es not_active Application Discontinuation
- 2003-08-04 AU AU2003258047A patent/AU2003258047A1/en not_active Abandoned
- 2003-08-04 JP JP2004543231A patent/JP2006504736A/ja active Pending
- 2003-10-10 US US10/684,227 patent/US7084151B2/en not_active Expired - Lifetime
-
2006
- 2006-06-02 US US11/445,844 patent/US20060223839A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2212052T3 (es) | Compuestos 1-ariloxi-2-arilnaftilo, intermedios, composiciones y procedimientos. | |
| CN101130567B (zh) | 新的抗雌激素甾族化合物、有关的药学组合物和使用方法 | |
| JP5886873B2 (ja) | Ｎ置換アゼチジン誘導体 | |
| JP5702929B2 (ja) | 認識機能障害（ｃｏｇｎｉｔｉｖｅｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５−ＨＴ３および５−ＨＴ１Ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）−フェニル］ピペラジン | |
| RU2002123047A (ru) | Селективные модуляторы рецептора эстрогена в комбинации с эстрогенами | |
| RU2001101487A (ru) | Медицинское применение селективного модулятора рецепторов эстрогенов в комбинации с предшественниками половых стероидных гормонов | |
| WO2021121210A1 (zh) | 并环类衍生物、其制备方法及其在医药上的应用 | |
| CA2632567A1 (en) | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors | |
| JP2006504736A5 (enExample) | ||
| CA3083028A1 (en) | Use of kor agonist in combination with mor agonist in preparing drug for treating pain | |
| TW200533636A (en) | Prodrugs of selective androgen receptor modulators and methods of use thereof | |
| ES2198462T3 (es) | Compuestos de naftilo y dihidronaftilo como medicamentos. | |
| WO2018233620A1 (zh) | SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 | |
| JP2009504768A5 (enExample) | ||
| JP2006508076A5 (enExample) | ||
| US8835493B2 (en) | Oligo-benzamide compounds for use in treating cancers | |
| PT826680E (pt) | Compostos di-hidronaftaleno e naftaleno intermediarios formulacoes e metodos para a sua preparacao | |
| TWI234458B (en) | Inhibition of the growth factor dependency of tumor cells | |
| CN114945570A (zh) | 雌激素受体调节剂的盐和形式 | |
| ES2222988T3 (es) | Formas de sal especificas de derivados de trifeniletileno como moduladores selectivos de los receptores de estrogenos. | |
| WO2020063407A1 (zh) | N-芳香酰胺类化合物及其制备方法和用途 | |
| CN114174297B (zh) | 雌激素受体调节化合物 | |
| CN105237474A (zh) | 6-羟基-7-芳甲酰基喹啉酮类化合物的制备及其应用 | |
| JP2006504737A5 (enExample) | ||
| TW201517910A (zh) | 黃體激素受體拮抗劑之劑型 |